Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITAS-301 itacitinib plus corticosteroids for first-line acute graft-versus-host disease
NL-OMON46651Phase 3Withdrawn
- Sponsor
- Incyte
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Incyte. Primary endpoint: Overall response rate at Day 28. Planned start Aug 2017; status: withdrawn.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON46651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46651.